Nuvalent (NASDAQ:NUVL) Reaches New 12-Month High – Here’s What Happened

Nuvalent, Inc. (NASDAQ:NUVL)’s share price reached a new 52-week high on Wednesday . The company traded as high as $123.62 and last traded at $123.5150, with a volume of 339209 shares traded. The stock had previously closed at $123.44.

Analyst Upgrades and Downgrades

Several research firms recently commented on NUVL. Robert W. Baird set a $122.85 target price on Nuvalent in a research note on Tuesday, June 9th. HC Wainwright cut Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price objective for the company. in a research note on Tuesday, June 9th. Barclays reissued an “equal weight” rating and set a $124.00 price objective (down from $152.00) on shares of Nuvalent in a research report on Tuesday, June 9th. Truist Financial cut shares of Nuvalent from a “buy” rating to a “hold” rating and reduced their target price for the company from $140.00 to $124.00 in a report on Tuesday, June 9th. Finally, Canaccord Genuity Group downgraded shares of Nuvalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 9th. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $127.73.

Nuvalent Price Performance

The firm has a 50 day moving average of $106.91 and a two-hundred day moving average of $104.16. The stock has a market cap of $9.76 billion, a PE ratio of -20.38 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the firm posted ($1.18) EPS. As a group, equities analysts anticipate that Nuvalent, Inc. will post -5.74 EPS for the current fiscal year.

Insider Activity at Nuvalent

In related news, insider Deborah Ann Miller sold 5,500 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total value of $593,120.00. Following the transaction, the insider directly owned 59,634 shares of the company’s stock, valued at $6,430,930.56. This trade represents a 8.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James Richard Porter sold 30,000 shares of Nuvalent stock in a transaction on Monday, June 8th. The stock was sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the sale, the chief executive officer owned 324,879 shares in the company, valued at $28,761,537.87. This represents a 8.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 126,953 shares of company stock worth $12,612,264. Corporate insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Nuvalent by 13.9% during the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after buying an additional 639,264 shares during the last quarter. Wellington Management Group LLP lifted its stake in Nuvalent by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 2,461,823 shares of the company’s stock valued at $247,635,000 after buying an additional 160,958 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Nuvalent by 32.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after acquiring an additional 545,542 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Nuvalent by 18.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,146,938 shares of the company’s stock valued at $215,962,000 after acquiring an additional 336,518 shares during the period. Finally, RA Capital Management L.P. grew its position in shares of Nuvalent by 50.8% during the fourth quarter. RA Capital Management L.P. now owns 1,880,057 shares of the company’s stock worth $189,115,000 after acquiring an additional 633,601 shares during the last quarter. Institutional investors and hedge funds own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.